UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K/A (Amendment No. 1)   (Mark One) ☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR  ☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
                     to Commission File Number 001-38503   Iterum Therapeutics plc (Exact name of Registrant as specified in its Charter)    Ireland

98-1283148(State or other jurisdiction of
incorporation or organization)

(I.R.S. EmployerIdentification No.) Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin
2, Ireland (Address of principal executive offices) Not applicable (Zip
Code) (+353) 1 903-8920 (Registrants telephone number, including area code)   Securities registered pursuant to Section 12(b) of the Act:  Title of each class

Trading Symbol(s)

Name of each exchange on which registeredOrdinary Shares, $0.01 par value per share

ITRM

The Nasdaq Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.    Yes  ☐    No  ☒ Indicate by check mark if the Registrant is not required
to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐    No  ☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.    Yes  ☒    No  ☐ Indicate by check mark whether the Registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the Registrant was required to submit such files).    Yes  ☒    No  ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.  Large accelerated filer

☐

Accelerated filer

☐Non-accelerated filer

☒

Smaller reporting company

☒Emerging growth company

☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒ Indicate by check mark whether the Registrant has filed a report on and attestation to its managements assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared or issued its audit report.  ☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the
Act).    Yes  ☐    No  ☒ The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the Registrants ordinary shares, $0.01 par value per share, on the
Nasdaq Global Market on June 28, 2019, the last business day of the Registrants most recently completed second fiscal quarter was $36,871,186. The number of shares of Registrants ordinary shares outstanding as of February 29, 2020 was 14,868,973.




---

EXPLANATORY NOTE This Amendment No. 1 on Form 10-K/A (Amendment No. 1) to the Annual Report on
Form 10-K of Iterum Therapeutics plc (the Company) for the year ended December 31, 2019, originally filed with the Securities and Exchange Commission on March 12, 2020 (the Original
Filing), is being filed solely to include revised Exhibits 31.1 and 31.2, to include certain wording required by Item 601(b)(31) of Regulation S-K inadvertently omitted by the Company when originally
filed. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 amends Item 15 to include new certifications as Exhibits 31.1 and 31.2. This Amendment
No. 1 contains only the cover page, this explanatory note, the signature page and the revised certifications. Because no financial statements are included with this Amendment No. 1, paragraph 3 of the certifications in Exhibits 31.1 and
31.2 has been omitted. This Amendment No. 1 does not update or amend any other items in the Original Filing in any way other than as
described in the preceding paragraph, and the Original Filing, as amended by this Amendment No. 1, continues to speak as of the date of the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original
Filing and the Companys other filings with the Securities and Exchange Commission.




---

PART IV  Item 15.
Exhibits and Financial Statement Schedules.  (a)
The following documents are filed as a part of this Amendment No. 1:  (3)
Exhibits The following exhibits:  Exhibit No.


Description of Document

Filedwith thisreport


Incorporated byReference hereinfrom Form orSchedule


Filing Date


SEC FileNumber31.1


Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934,
 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


X31.2


Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934,
 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


X




---

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused
this Report to be signed on its behalf by the undersigned, thereunto duly authorized.  ITERUM THERAPEUTICS PLCDate: August 6, 2020



By:

/s/ Corey N. FishmanCorey N. FishmanPresident and Chief Executive Officer